

Literaturverzeichnis

1. Murer H, Biber J: Membrane permeability. Epithelial transport proteins: physiology and pathophysiology. *Curr Opin Cell Biol* 10:429-434, 1998
2. Rodriguez-Boulan E, Zurzolo C: Polarity signals in epithelial cells. *J Cell Sci Suppl* 17:9-12, 1993
3. Simmons C: The development of cellular polarity in transport epithelia. *Semin Perinatol* 16:78-89, 1992
4. Stein M, Wandinger-Ness A, Roitbak T: Altered trafficking and epithelial cell polarity in disease. *Trends Cell Biol* 12:374-381, 2002
5. Brown D, Sabolic I, Breton S: Polarized expression of membrane proteins in renal epithelial cells: involvement of specialized transport vesicles and intracellular pathways. *Adv Nephrol Necker Hosp* 27:297-315, 1997
6. Caplan MJ: Membrane polarity in epithelial cells: protein sorting and establishment of polarized domains. *Am J Physiol* 272:F425-F429, 1997
7. Cereijido M, Shoshani L, Contreras RG: Molecular Physiology and Pathophysiology of Tight Junctions I. Biogenesis of tight junctions and epithelial polarity. *Am J Physiol Gastrointest Liver Physiol* 279:G477-G482, 2000
8. Bojarski C, Gitter AH, Bendfeldt K, Mankertz J, Schmitz H, Wagner S, Fromm M, Schulzke JD: Permeability of human HT-29/B6 colonic epithelium as a function of apoptosis. *J Physiol* 535:541-552, 2001
9. Chlenski A, Ketels KV, Tsao MS, Talamonti MS, Anderson MR, Oyasu R, Scarpelli DG: Tight junction protein ZO-2 is differentially expressed in normal pancreatic ducts compared to human pancreatic adenocarcinoma. *Int J Cancer* 82:137-144, 1999
10. Chen Yh, Lu Q, Schneeberger EE, Goodenough DA: Restoration of Tight Junction Structure and Barrier Function by Down-Regulation of the Mitogen-activated Protein Kinase Pathway in Ras-transformed Madin-Darby Canine Kidney Cells. *Mol.Biol.Cell* 11:849-862, 2000
11. Long H, Crean CD, Lee WH, Cummings OW, Gabig TG: Expression of Clostridium Perfringens Enterotoxin Receptors Claudin-3 and Claudin-4 in Prostate Cancer Epithelium. *Cancer Res* 61:7878-7881, 2001
12. Paul JW, Kotz KW, Roche JK: Sensitization to epithelial antigens in chronic mucosal inflammatory disease: immunochemical similarity of macromolecules in human colonic epithelium with murine intestinal epithelial cell-associated components (ECAC). *Immunology* 65:551-557, 1988
13. Gitter AH, Wullstein F, Fromm M, Schulzke JD: Epithelial barrier defects in ulcerative colitis: characterization and quantification by electrophysiological imaging. *Gastroenterology* 121:1320-1328, 2001

14. Gitter AH, Bendfeldt K, Schmitz H, Schulzke JD, Bentzel CJ, Fromm M: Epithelial barrier defects in HT-29/B6 colonic cell monolayers induced by tumor necrosis factor-alpha. *Ann N Y Acad Sci* 915:193-203, 2000
15. Gitter AH, Bendfeldt K, Schulzke JD, Fromm M: Leaks in the epithelial barrier caused by spontaneous and TNF-alpha-induced single-cell apoptosis. *FASEB J* 14:1749-1753, 2000
16. Blazer-Yost BL, Liu X, Helman SI: Hormonal regulation of ENaCs: insulin and aldosterone. *Am J Physiol* 274:C1373-C1379, 1998
17. Halm DR: Rapid actions of steroids. Focus on "Nongenomic regulation of ENaC by aldosterone". *Am J Physiol Cell Physiol* 281:C1094-C1095, 2001
18. Masilamani S, Kim GH, Mitchell C, Wade JB, Knepper MA: Aldosterone-mediated regulation of ENaC alpha, beta, and gamma subunit proteins in rat kidney. *J Clin Invest* 104:R19-R23, 1999
19. Denker BM, Nigam SK: Molecular structure and assembly of the tight junction. *Am J Physiol* 274:F1-F9, 1998
20. Karczewski J, Groot J: Molecular Physiology and Pathophysiology of Tight Junctions III. Tight junction regulation by intracellular messengers: differences in response within and between epithelia. *Am J Physiol Gastrointest Liver Physiol* 279:G660-G665, 2000
21. Itoh M, Furuse M, Morita K, Kubota K, Saitou M, Tsukita S: Direct Binding of Three Tight Junction-associated MAGUKs, ZO-1, ZO-2, and ZO-3, with the COOH Termini of Claudins. *J Cell Biol* 147:1351-1363, 1999
22. Schneeberger EE: Claudins form ion-selective channels in the paracellular pathway. Focus on "Claudin extracellular domains determine paracellular charge selectively and resistance but not tight junction fibril architecture". *Am J Physiol Cell Physiol* 284:C1331-C1333, 2003
23. Wilcox Edward R, Burton Quianna L, Naz Sadaf, Riazuddin Saima, Smith Tenesha N, Ploplis Barbara, Belyantseva Inna, Ben-yosef Tamar, Liburd Nikki A, Morell Robert J, Kachar Bechara, Wu Doris K, Griffith Andrew J, Riazuddin Sheikh, Friedman Thomas B: Mutations in the gene encoding tight junction claudin-14 cause autosomal recessive deafness DFNB29. *Cell* 104:165-172, 2004
24. Ben Yosef T, Belyantseva IA, Saunders TL, Hughes ED, Kawamoto K, Van Itallie CM, Beyer LA, Halsey K, Gardner DJ, Wilcox ER, Rasmussen J, Anderson JM, Dolan DF, Forge A, Raphael Y, Camper SA, Friedman TB: Claudin 14 knockout mice, a model for autosomal recessive deafness DFNB29, are deaf due to cochlear hair cell degeneration. *Hum Mol Genet* 12:2049-2061, 2003
25. Simon DB, Lu Y, Choate KA, Velazquez H, Al Sabban E, Praga M, Casari G, Bettinelli A, Colussi G, Rodriguez-Soriano J, McCredie D, Milford D, Sanjad S, Lifton RP: Paracellin-1, a renal tight junction protein required for paracellular Mg²⁺ resorption. *Science* 285:103-106, 1999

26. Christensen EI, Verroust PJ: Megalin and cubilin, role in proximal tubule function and during development.
Pediatr Nephrol 17:993-999, 2002
27. Birn H, Willnow TE, Nielsen R, Norden AG, Bonsch C, Moestrup SK, Nexø E, Christensen EI: Megalin is essential for renal proximal tubule reabsorption and accumulation of transcobalamin-B(12).
Am J Physiol Renal Physiol 282:F408-F416, 2002
28. Muller D, Nykjaer A, Willnow TE: From holoprosencephaly to osteopathology: role of multifunctional endocytic receptors in absorptive epithelia.
Ann Med 35:290-299, 2003
29. Schmitz C, Hilpert J, Jacobsen C, Boensch C, Christensen EI, Luft FC, Willnow TE: Megalin deficiency offers protection from renal aminoglycoside accumulation.
J Biol Chem 277:618-622, 2002
30. Christensen EI, Willnow TE: Essential role of megalin in renal proximal tubule for vitamin homeostasis.
J Am Soc Nephrol 10:2224-2236, 1999
31. Gburek J, Birn H, Verroust PJ, Goj B, Jacobsen C, Moestrup SK, Willnow TE, Christensen EI: Renal uptake of myoglobin is mediated by the endocytic receptors megalin and Cubilin.
Am J Physiol Renal Physiol 285:F451-F458, 2003
32. Christensen EI, Moskaug JO, Vorum H, Jacobsen C, Gundersen TE, Nykjaer A, Blomhoff R, Willnow TE, Moestrup SK: Evidence for an essential role of megalin in transepithelial transport of retinol.
J Am Soc Nephrol 10:685-695, 1999
33. Aminoff M, Carter JE, Chadwick RB, Johnson C, Grasbeck R, Abdelaal MA, Broch H, Jenner LB, Verroust PJ, Moestrup SK, de la CA, Krahe R: Mutations in CUBN, encoding the intrinsic factor-vitamin B12 receptor, cubilin, cause hereditary megaloblastic anaemia 1.
Nat Genet 21:309-313, 1999
34. Wahlstedt-Froberg V, Pettersson T, Aminoff M, Dugue B, Grasbeck R: Proteinuria in cubilin-deficient patients with selective vitamin B12 malabsorption.
Pediatr Nephrol 18:417-421, 2003
35. Leheste JR, Rolinski B, Vorum H, Hilpert J, Nykjaer A, Jacobsen C, Aucouturier P, Moskaug JO, Otto A, Christensen EI, Willnow TE: Megalin knockout mice as an animal model of low molecular weight proteinuria.
Am J Pathol 155:1361-1370, 1999
36. Birkenhager R, Otto E, Schurmann MJ, Vollmer M, Ruf EM, Maier-Lutz I, Beekmann F, Fekete A, Omran H, Feldmann D, Milford DV, Jeck N, Konrad M, Landau D, Knoers NV, Antignac C, Sudbrak R, Kispert A, Hildebrandt F: Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure. Nat Genet 29:310-314, 2001

37. Estevez R, Boettger T, Stein V, Birkenhager R, Otto E, Hildebrandt F, Jentsch TJ: Barttin is a Cl⁻ channel beta-subunit crucial for renal Cl⁻ reabsorption and inner ear K⁺ secretion. *Nature* 414:558-561, 2001
38. Simon DB, Bindra RS, Mansfield TA, Nelson-Williams C, Mendonca E, Stone R, Schurman S, Nayir A, Alpay H, Bakkaloglu A, Rodriguez-Soriano J, Morales JM, Sanjad SA, Taylor CM, Pilz D, Brem A, Trachtman H, Griswold W, Richard GA, John E, Lifton RP: Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome type III. *Nat Genet* 17:171-178, 1997
39. Simon DB, Karet FE, Rodriguez-Soriano J, Hamdan JH, DiPietro A, Trachtman H, Sanjad SA, Lifton RP: Genetic heterogeneity of Bartter's syndrome revealed by mutations in the K⁺ channel, ROMK. *Nat Genet* 14:152-156, 1996
40. Simon DB, Karet FE, Hamdan JM, DiPietro A, Sanjad SA, Lifton RP: Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. *Nat Genet* 13:183-188, 1996
41. Vargas-Poussou R, Feldmann D, Vollmer M, Konrad M, Kelly L, van den Heuvel LP, Tebourbi L, Brandis M, Karolyi L, Hebert SC, Lemmink HH, Deschenes G, Hildebrandt F, Seyberth HW, Guay-Woodford LM, Knoers NV, Antignac C: Novel molecular variants of the Na-K-2Cl cotransporter gene are responsible for antenatal Bartter syndrome. *Am J Hum Genet* 62:1332-1340, 1998
42. Konrad M, Vollmer M, Lemmink HH, van den Heuvel LP, Jeck N, Vargas-Poussou R, Lakings A, Ruf R, Deschenes G, Antignac C, Guay-Woodford L, Knoers NV, Seyberth HW, Feldmann D, Hildebrandt F: Mutations in the chloride channel gene CLCNKB as a cause of classic Bartter syndrome. *J Am Soc Nephrol* 11:1449-1459, 2000
43. Loffing J, Loffing-Cueni D, Valderrabano V, Klausli L, Hebert SC, Rossier BC, Hoenderop JG, Bindels RJ, Kaissling B: Distribution of transcellular calcium and sodium transport pathways along mouse distal nephron. *Am J Physiol Renal Physiol* 281:F1021-F1027, 2001
44. Ellison DH: Divalent cation transport by the distal nephron: insights from Bartter's and Gitelman's syndromes. *Am J Physiol Renal Physiol* 279:F616-F625, 2000
45. Muller D, Hoenderop JGJ, van Os CH, Bindels JM: The epithelial calcium channel, ECaC1: molecular details of a novel player in renal calcium handling. *Nephrol Dial Transplant*. 16:1329-1335, 2001
46. Karolyi L, Ziegler A, Pollak M, Fischbach M, Grzeschik KH, Koch MC, Seyberth HW: Gitelman's syndrome is genetically distinct from other forms of Bartter's syndrome. *Pediatr Nephrol* 10:551-554, 1996
47. Simon DB, Nelson-Williams C, Bia MJ, Ellison D, Karet FE, Molina AM, Vaara I, Iwata F, Cushner HM, Koolen M, Gainza FJ, Gitleman HJ, Lifton RP: Gitelman's

variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter.
Nat Genet 12:24-30, 1996

48. Smith AN, Skaug J, Choate KA, Nayir A, Bakkaloglu A, Ozen S, Hulton SA, Sanjad SA, Al Sabban EA, Lifton RP, Scherer SW, Karet FE: Mutations in ATP6N1B, encoding a new kidney vacuolar proton pump 116-kD subunit, cause recessive distal renal tubular acidosis with preserved hearing.
Nat Genet 26:71-75, 2000
49. Karet FE, Finberg KE, Nelson RD, Nayir A, Mocan H, Sanjad SA, Rodriguez-Soriano J, Santos F, Cremers CW, Di Pietro A, Hoffbrand BI, Winiarski J, Bakkaloglu A, Ozen S, Dusunsel R, Goodyer P, Hulton SA, Wu DK, Skvorak AB, Morton CC, Cunningham MJ, Jha V, Lifton RP: Mutations in the gene encoding B1 subunit of H⁺-ATPase cause renal tubular acidosis with sensorineural deafness.
Nat Genet 21:84-90, 1999
50. Karet FE, Gainza FJ, Gyory AZ, Unwin RJ, Wrong O, Tanner MJ, Nayir A, Alpay H, Santos F, Hulton SA, Bakkaloglu A, Ozen S, Cunningham MJ, Di Pietro A, Walker WG, Lifton RP: Mutations in the chloride-bicarbonate exchanger gene AE1 cause autosomal dominant but not autosomal recessive distal renal tubular acidosis.
Proc Natl Acad Sci U S A 95:6337-6342, 1998
51. Barakat AJ, Rennert OM: Gitelman's syndrome (familial hypokalemia-hypomagnesemia). *J Nephrol* 14:43-47, 2001
52. Ariceta G, Rodriguez-Soriano J, Vallo A: Renal magnesium handling in infants and children. *Acta Paediatr.* 85:1019-1023, 1996
53. Peng JB, Chen XZ, Berger UV, Vassilev PM, Tsukaguchi H, Brown EM, Hediger MA: Molecular cloning and characterization of a channel-like transporter mediating intestinal calcium absorption. *J Biol Chem* 274:22739-22746, 1999
54. Hoenderop JG, van der Kemp AW, Hartog A, van de Graaf SF, Van Os CH, Willems PH, Bindels RJ: Molecular identification of the apical Ca²⁺ channel in 1, 25-dihydroxyvitamin D₃-responsive epithelia.
J Biol Chem 274:8375-8378, 1999
55. Muller D, Hoenderop JG, Merckx GF, Van Os CH, Bindels RJ: Gene structure and chromosomal mapping of human epithelial calcium channel. *Biochem Biophys Res Commun* 275:47-52, 2000
56. Clapham DE, Runnels LW, Strubing C: The TRP ion channel family.
Nat Rev Neurosci 2:387-396, 2001
57. Glendenning P, Ratajczak T, Dick IM, Prince RL: Calcitriol upregulates expression and activity of the 1b isoform of the plasma membrane calcium pump in immortalized distal kidney tubular cells.
Arch Biochem Biophys 380:126-132, 2000
58. Sooy K, Kohut J, Christakos S: The role of calbindin and 1,25dihydroxyvitamin D₃ in the kidney.
Curr Opin Nephrol Hypertens 9:341-347, 2000

59. Gross M, Kumar R: Physiology and biochemistry of vitamin D-dependent calcium binding proteins.
Am J Physiol 259:F195-F209, 1990
60. Zehnder D, Hewison M: The renal function of 25-hydroxyvitamin D₃-1 α -hydroxylase.
Mol Cell Endocrinol 151:213-220, 1999
61. DeLuca HF: The kidney as an endocrine organ for the production of 1,25-dihydroxyvitamin D₃, a calcium-mobilizing hormone.
N Engl J Med 289:359-365, 1973
62. Brown EM: Mutations in the calcium-sensing receptor and their clinical implications.
Horm Res 48:199-208, 1997
63. Garrett JE, Capuano IV, Hammerland LG, Hung BC, Brown EM, Hebert SC, Nemeth EF, Fuller F: Molecular cloning and functional expression of human parathyroid calcium receptor cDNAs. J Biol Chem 270:12919-12925, 1995
64. Kos CH, Karaplis AC, Peng JB, Hediger MA, Goltzman D, Mohammad KS, Guise TA, Pollak MR: The calcium-sensing receptor is required for normal calcium homeostasis independent of parathyroid hormone.
J Clin Invest 111:1021-1028, 2003
65. Knohl SJ, Scheinman SJ: Inherited hypercalciuric syndromes: Dent's disease (CLC-5) and familial hypomagnesemia with hypercalciuria (paracellin-1).
Semin Nephrol 24:55-60, 2004
66. Flagg TP, Yoo D, Sciortino CM, Tate M, Romero MF, Welling PA: Molecular mechanism of a COOH-terminal gating determinant in the ROMK channel revealed by a Bartter's disease mutation. J Physiol 544:351-362, 2002
67. Kockerling A, Reinalter SC, Seyberth HW: Impaired response to furosemide in hyperprostaglandin E syndrome: evidence for a tubular defect in the loop of Henle. J Pediatr 129:519-528, 1996
68. Kunzelmann K, Hubner M, Vollmer M, Ruf R, Hildebrandt F, Greger R, Schreiber R: A Bartter's syndrome mutation of ROMK1 exerts dominant negative effects on K(+) conductance.
Cell Physiol Biochem. 10:117-124, 2000
69. Alon U, Warady BA, Hellerstein S: Hypercalciuria in the frequency-dysuria syndrome of childhood.
J Pediatr 116:103-105, 1990
70. Alon US, Berenbom A: Idiopathic hypercalciuria of childhood: 4- to 11-year outcome
Pediatr Nephrol 14:1011-1015, 2000
71. Bercem G, Cevit O, Toksoy HB, Icagasioglu D, Gultekin A, Tanzer F: Asymptomatic hypercalciuria: prevalence and metabolic characteristics. Indian J Pediatr 68:315-318, 2001

72. Hasanoglu A, Ercan ZS, Buyan N, Memioglu N, Hasanoglu E: Parathormone, 1,25 dihydroxyvitamin D and prostaglandin E2 correlation in children with idiopathic hypercalciuria.
Prostaglandins Leukot Essent Fatty Acids 56:235-237, 1997
73. Polito C, La Manna A, Cioce F, Villani J, Nappi B, Di Toro R: Clinical presentation and natural course of idiopathic hypercalciuria in children.
Pediatr.Nephrol 15:211-214, 2000
74. Vachvanichsanong P, Malagon M, Moore ES: Urinary incontinence due to idiopathic hypercalciuria in children.
J Urol 152:1226-1228, 1994
75. Vachvanichsanong P, Malagon M, Moore ES: Urinary tract infection in children associated with idiopathic hypercalciuria.
Scand J Urol Nephrol 35:112-116, 2001
76. Parekh DJ, Pope JC, Adams MC, Brock JW, III: The association of an increased urinary calcium-to-creatinine ratio, and asymptomatic gross and microscopic hematuria in children.
J Urol 167:272-274, 2002
77. Stapleton FB, Roy S, III, Noe HN, Jerkins G: Hypercalciuria in children with hematuria.
N Engl J Med 310:1345-1348, 1984
78. Polinsky MS, Kaiser BA, Baluarte HJ, Gruskin AB: Renal stones and hypercalciuria.
Adv Pediatr 40:353-384, 1993
79. Freundlich M, Alonzo E, Bellorin-Font E, Weisinger JR: Reduced bone mass in children with idiopathic hypercalciuria and in their asymptomatic mothers
Nephrol Dial Transplant 17:1396-1401, 2002
80. Garcia-Nieto V, Ferrandez C, Monge M, de Sequera M, Rodrigo MD: Bone mineral density in pediatric patients with idiopathic hypercalciuria. *Pediatr Nephrol* 11:578-583, 1997
81. Garcia-Nieto V, Navarro JF, Monge M, Garcia-Rodriguez VE: Bone mineral density in girls and their mothers with idiopathic hypercalciuria.
Nephron Clin Pract 94:c89-c93, 2003
82. Misael da Silva AM, dos Reis LM, Pereira RC, Futata E, Branco-Martins CT, Noronha IL, Wajchemberg BL, Jorgetti V: Bone involvement in idiopathic hypercalciuria.
Clin Nephrol 57:183-191, 2002
83. Polito C, Iolascon G, Nappi B, Andreoli S, La Manna A: Growth and bone mineral density in long-lasting idiopathic hypercalciuria.
Pediatr Nephrol 18:545-547, 2003
84. Pace G, Aceto G, Cormio L, Traficante A, Tempesta A, Lospalluti ML, Selvaggi FP, Penza R: Nocturnal enuresis can be caused by absorptive hypercalciuria.
Scand J Urol Nephrol 33:111-114, 1999

85. Pak CY, Kaplan R, Bone H, Townsend J, Waters O: A simple test for the diagnosis of absorptive, resorptive and renal hypercalciurias. *N Engl J Med* 292:497-500, 1975
86. Coe FL, Favus MJ: Idiopathic hypercalciuria in calcium nephrolithiasis. *Dis Mon* 26:1-36, 1980
87. Aladjem M, Barr J, Lahat E, Bistritzer T: Renal and absorptive hypercalciuria: a metabolic disturbance with varying and interchanging modes of expression. *Pediatrics* 97:216-219, 1996
88. Moore ES, Coe FL, McMann BJ, Favus MJ: Idiopathic hypercalciuria in children: prevalence and metabolic characteristics. *J Pediatr* 92:906-910, 1978
89. Nicolaidou P, Themeli S, Karpathios T, Georgouli H, Athanassaki K, Xaidara A, Messaritakis J: Family pattern of idiopathic hypercalciuria and its subtypes. *J Urol* 155:1042-1044, 1996
90. Zerwekh JE, Hughes MR, Reed BY, Breslau NA, Heller HJ, Lemke M, Nasonkin I, Pak CY: Evidence for normal vitamin D receptor messenger ribonucleic acid and genotype in absorptive hypercalciuria. *J Clin Endocrinol Metab* 80:2960-2965, 1995
91. Zerwekh JE, Reed BY, Heller HJ, Gonzalez GB, Haussler MR, Pak CY: Normal vitamin D receptor concentration and responsiveness to 1, 25-dihydroxyvitamin D₃ in skin fibroblasts from patients with absorptive hypercalciuria. *Miner Electrolyte Metab* 24:307-313, 1998
92. Harangi F, Mehes K: Family investigations in idiopathic hypercalciuria. *Eur J Pediatr* 152:64-68, 1993
93. Coe FL, Parks JH, Moore ES: Familial idiopathic hypercalciuria. *N.Engl.J Med* 300:337-340, 1979
94. Pak CY, McGuire J, Peterson R, Britton F, Harrod MJ: Familial absorptive hypercalciuria in a large kindred. *J Urol* 126:717-719, 1981
95. Praga M, Alegre R, Hernandez E, Morales E, Dominguez-Gil B, Carreno A, Andres A: Familial microscopic hematuria caused by hypercalciuria and hyperuricosuria. *Am J Kidney Dis.* 35:141-145, 2000
96. Scott P, Ouimet D, Proulx Y, Trouve ML, Guay G, Gagnon B, Valiquette L, Bonnardeaux A: The 1 alpha-hydroxylase locus is not linked to calcium stone formation or calciuric phenotypes in French-Canadian families. *J Am Soc Nephrol* 9:425-432, 1998
97. Lerolle N, Coulet F, Lantz B, Paillard F, Houillier P, Soubrier F, Gattegno B, Jeunemaitre X, Ronco P, Rondeau E: No evidence for point mutations of the calcium-sensing receptor in familial idiopathic hypercalciuria. *Nephrol Dial Transplant* 16:2317-2322, 2001

98. Reed BY, Heller HJ, Gitomer WL, Pak CY: Mapping a gene defect in absorptive hypercalciuria to chromosome 1q23.3-q24. *J Clin Endocrinol Metab* 84:3907-3913, 1999
99. Reed BY, Gitomer WL, Heller HJ, Hsu MC, Lemke M, Padalino P, Pak CY: Identification and characterization of a gene with base substitutions associated with the absorptive hypercalciuria phenotype and low spinal bone density. *J Clin Endocrinol Metab* 87:1476-1485, 2002
100. Hymes LC, Warshaw BL: Thiazide diuretics for the treatment of children with idiopathic hypercalciuria and hematuria. *J Urol* 138:1217-1219, 1987
101. Barakat AJ, Rennert OM: Gitelman's syndrome (familial hypokalemia-hypomagnesemia). *J Nephrol* 14:43-47, 2001
102. Ellison DH: Divalent cation transport by the distal nephron: insights from Bartter's and Gitelman's syndromes. *Am J Physiol Renal Physiol* 279:F616-F625, 2000
103. Hulton SA: Evaluation of urinary tract calculi in children. *Arch Dis Child* 84:320-323, 2001
104. Knoers NV, de Jong JC, Meij IC, van den Heuvel LP, Bindels RJ: Genetic renal disorders with hypomagnesemia and hypocalciuria. *J Nephrol* 16:293-296, 2003
105. Konrad M, Schlingmann KP, Gudermann T: Insights into the molecular nature of magnesium homeostasis. *Am J Physiol Renal Physiol* 286:F599-F605, 2004
106. Dai LJ, Ritchie G, Kerstan D, Kang HS, Cole DEC, Quamme GA: Magnesium Transport in the Renal Distal Convoluted Tubule. *Physiol Rev* 81:51-84, 2001
107. Satoh J, Romero MF: Mg²⁺ transport in the kidney. *Biometals* 15:285-295, 2002
108. Kockerling A, Reinalter SC, Seyberth HW: Impaired response to furosemide in hyperprostaglandin E syndrome: evidence for a tubular defect in the loop of Henle. *J Pediatr*. 129:519-528, 1996
109. Meij IC, Saar K, van den Heuvel LP, Nuernberg G, Vollmer M, Hildebrandt F, Reis A, Monnens LA, Knoers NV: Hereditary isolated renal magnesium loss maps to chromosome 11q23. *Am J Hum Genet* 64:180-188, 1999
110. Meij IC, Koenderink JB, De Jong JC, De Pont JJ, Monnens LAH, Van Den Heuvel LPWJ, Knoers NVAM: Dominant Isolated Renal Magnesium Loss Is Caused by Misrouting of the Na⁺,K⁺-ATPase (gamma)-Subunit. *Ann NY Acad Sci* 986:437-443, 2003
111. Weber S, Schneider L, Peters M, Misselwitz J, Ronnefarth G, Boswald M, Bonzel KE, Seeman T, Sulakova T, Kuwertz-Broking E, Gregoric A, Palcoux JB, Tasic V, Manz F, Scharer K, Seyberth HW, Konrad M: Novel paracellin-1 mutations in 25 families with familial hypomagnesemia with hypercalciuria and nephrocalcinosis. *J Am Soc Nephrol* 12:1872-1881, 2001

112. Wolf MT, Dotsch J, Konrad M, Boswald M, Rascher W: Follow-up of five patients with FHHNC due to mutations in the Paracellin-1 gene. *Pediatr Nephrol* 17:602-608, 2002
113. Blanchard A, Jeunemaitre X, Coudol P, Dechaux M, Froissart M, May A, Demontis R, Fournier A, Paillard M, Houillier P: Paracellin-1 is critical for magnesium and calcium reabsorption in the human thick ascending limb of Henle. *Kidney Int* 59:2206-2215, 2001
114. Walder RY, Landau D, Meyer P, Shalev H, Tsolia M, Borochoowitz Z, Boettger MB, Beck GE, Englehardt RK, Carmi R, Sheffield VC: Mutation of TRPM6 causes familial hypomagnesemia with secondary hypocalcemia. *Nat Genet* 31:171-174, 2002
115. Schlingmann KP, Weber S, Peters M, Niemann NL, Vitzthum H, Klingel K, Kratz M, Haddad E, Ristoff E, Dinour D, Syrrou M, Nielsen S, Sassen M, Waldegger S, Seyberth HW, Konrad M: Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. *Nat Genet* 31:166-170, 2002
116. Schmitz C, Perraud AL, Fleig A, Scharenberg AM: Dual-function ion channel/protein kinases: novel components of vertebrate magnesium regulatory mechanisms. *Pediatr Res* 55:734-737, 2004
117. Perraud AL, Knowles HM, Schmitz C: Novel aspects of signaling and ion-homeostasis regulation in immunocytes; The TRPM ion channels and their potential role in modulating the immune response. *Mol Immunol* 41:657-673, 2004
118. Voets T, Nilius B, Hoefs S, van der Kemp AWCM, Droogmans G, Bindels RJM, Hoenderop JGJ: TRPM6 Forms the Mg²⁺ Influx Channel Involved in Intestinal and Renal Mg²⁺ Absorption. *J Biol Chem* 279:19-25, 2004
119. Chubanov V, Waldegger S, Schnitzler M, Vitzthum H, Sassen MC, Seyberth HW, Konrad M, Gudermann T: Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6 gene causes hypomagnesemia with secondary hypocalcemia. *Proc Natl Acad Sci U S A* 101:2894-2899, 2004
120. Brown D: Structural-functional features of antidiuretic hormone-induced water transport in the collecting duct. *Semin Nephrol* 11:478-501, 1991
121. Edwards CR: Vasopressin and oxytocin in health and disease. *Clin Endocrinol Metab* 6:223-259, 1977
122. Kamsteeg EJ, Wormhoudt TA, Rijss JP, Van Os CH, Deen PM: An impaired routing of wild-type aquaporin-2 after tetramerization with an aquaporin-2 mutant explains dominant nephrogenic diabetes insipidus. *EMBO J* 18:2394-2400, 1999

123. Marr N, Bichet DG, Lonergan M, Arthus MF, Jeck N, Seyberth HW, Rosenthal W, Van Os CH, Oksche A, Deen PM: Heteroligomerization of an Aquaporin-2 mutant with wild-type Aquaporin-2 and their misrouting to late endosomes/lysosomes explains dominant nephrogenic diabetes insipidus. *Hum Mol Genet* 11:779-789, 2002
124. Yun J, Schoneberg T, Liu J, Schulz A, Ecelbarger CA, Promeneur D, Nielsen S, Sheng H, Grinberg A, Deng C, Wess J: Generation and phenotype of mice harboring a nonsense mutation in the V2 vasopressin receptor gene. *J Clin Invest* 106:1361-1371, 2000
125. Ala Y, Morin D, Mouillac B, Sabatier N, Vargas R, Cotte N, Dechaux M, Antignac C, Arthus MF, Lonergan M, Turner MS, Balestre MN, Alonso G, Hibert M, Barberis C, Hendy GN, Bichet DG, Jard S: Functional studies of twelve mutant V2 vasopressin receptors related to nephrogenic diabetes insipidus: molecular basis of a mild clinical phenotype. *J Am Soc Nephrol* 9:1861-1872, 1998
126. Oksche A, Schulein R, Rutz C, Liebenhoff U, Dickson J, Muller H, Birnbaumer M, Rosenthal W: Vasopressin V2 receptor mutants that cause X-linked nephrogenic diabetes insipidus: analysis of expression, processing, and function. *Mol Pharmacol* 50:820-828, 1996
127. Pan Y, Metzenberg A, Das S, Jing B, Gitschier J: Mutations in the V2 vasopressin receptor gene are associated with X-linked nephrogenic diabetes insipidus. *Nat Genet* 2:103-106, 1992
128. Brink HS, Derkx FH, Boomsma F, Brommer EJ, Schalekamp MA: 1-Desamino-8-D-arginine vasopressin (DDAVP) in patients with congenital nephrogenic diabetes insipidus. *Neth J Med* 43:5-12, 1993
129. Hirasawa A, Shibata K, Kotosai K, Tsujimoto G: Cloning, functional expression and tissue distribution of human cDNA for the vascular-type vasopressin receptor. *Biochem Biophys Res Commun* 203:72-79, 1994
130. Ostrowski NL, Young WS, III, Knepper MA, Lolait SJ: Expression of vasopressin V1a and V2 receptor messenger ribonucleic acid in the liver and kidney of embryonic, developing, and adult rats. *Endocrinology* 133:1849-1859, 1993
131. Richardson DW, Robinson AG: Desmopressin. *Ann Intern.Med* 103:228-239, 1985
132. Kaufmann JE, Vischer UM: Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). *J Thromb.Haemost.* 1:682-689, 2003
133. Kaufmann JE, Oksche A, Wollheim CB, Gunther G, Rosenthal W, Vischer UM: Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. *J Clin Invest* 106:107-116, 2000

134. Mannucci PM, Federici AB: Management of inherited von Willebrand disease. *Best Pract Res Clin Haematol* 14:455-462, 2001
135. Robson WL, Leung AK: Secondary nocturnal enuresis. *Clin Pediatr (Phila)* 39:379-385, 2000
136. American Psychiatric Association: Diagnostic and statistic manual of mental disorders. DSM IV, 4th edition. Washington, DC, 1995
137. Deutsche Gesellschaft für Kinder- und Jugendpsychiatrie u.a.(Hrsg.): Leitlinien zur Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes- und Jugendalter. 2. überarbeitete Auflage, 2003. Deutscher Ärzteverlag, 2003
138. Norgaard JP, van Gool JD, Hjalmas K, Djurhuus JC, Hellstrom AL: Standardization and definitions in lower urinary tract dysfunction in children. *Br J Urol* 81 Suppl:1-16, 1998
139. Deutsches Institut für medizinische Dokumentation und Information (DIMDI): ICD-10-SGBV. Internationale statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme. 10. Revision, Deutscher Ärzteverlag, Köln 1999
140. Bachmann H: Einnässen/Inkontinenz. In: Leitlinien Kinderheilkunde und Jugendmedizin. Deutsche Gesellschaft für Kinder- und Jugendmedizin. Urban und Fischer, 2003, pp 46-48
141. Byrd RS, Weitzman M, Lanphear NE, Auinger P: Bed-wetting in US children: epidemiology and related behavior problems. *Pediatrics* 98:414-419, 1996
142. Yeung CK, Sihoe JD, Sit FK, Bower W, Sreedhar B, Lau J: Characteristics of primary nocturnal enuresis in adults: an epidemiological study. *BJU Int* 93:341-345, 2004
143. Butler RJ: Impact of nocturnal enuresis on children and young people. *Scand.J Urol Nephrol* 35:169-176, 2001
144. Longstaffe S, Moffatt ME, Whalen JC: Behavioral and self-concept changes after six months of enuresis treatment: a randomized, controlled trial. *Pediatrics* 105:935-940, 2000
145. Schulpen TW: The burden of nocturnal enuresis. *Acta Paediatr.* 86:981-984, 1997
146. Theunis M, Van Hoecke E, Paesbrugge S, Hoebeke P, Vande WJ: Self-image and performance in children with nocturnal enuresis. *Eur Urol* 41:660-667, 2002
147. Glazener CM, Evans JH, Peto RE: Tricyclic and related drugs for nocturnal enuresis in children. *Cochrane Database Syst Rev* CD002117, 2003
148. Smellie JM, McGrigor VS, Meadow SR, Rose SJ, Douglas MF: Nocturnal enuresis: a placebo controlled trial of two antidepressant drugs.

- Arch Dis Child 75:62-66, 1996
149. Glazener CM, Evans JH, Peto RE: Alarm interventions for nocturnal enuresis in children.
Cochrane Database Syst Rev CD002911, 2003
 150. Glazener CM, Evans JH: Desmopressin for nocturnal enuresis in children.
Cochrane Database Syst Rev CD002112, 2002
 151. Yeung CK, Sit FK, To LK, Chiu HN, Sihoe JD, Lee E, Wong C: Reduction in nocturnal functional bladder capacity is a common factor in the pathogenesis of refractory nocturnal enuresis.
BJU Int 90:302-307, 2002
 152. Yeung CK, Chiu HN, Sit FK: Bladder dysfunction in children with refractory monosymptomatic primary nocturnal enuresis. J Urol 162:1049-1054, 1999
 153. Hamano S, Yamanishi T, Igarashi T, Ito H, Murakami S: Functional bladder capacity as predictor of response to desmopressin and retention control training in monosymptomatic nocturnal enuresis. Eur Urol 37:718-722, 2000
 154. Rittig S, Knudsen UB, Norgaard JP, Gregersen H, Pedersen EB, Djurhuus JC: Diurnal variation of plasma atrial natriuretic peptide in normals and patients with enuresis nocturna.
Scand J Clin Lab Invest 51:209-217, 1991
 155. Birkasova M, Birkas O, Flynn MJ, Cort JH: Desmopressin in the management of nocturnal enuresis in children: a double-blind study.
Pediatrics 62:970-974, 1978
 156. Aladjem M, Wohl R, Boichis H, Orda S, Lotan D, Freedman S: Desmopressin in nocturnal enuresis.
Arch Dis Child 57:137-140, 1982
 157. Tuvemo T: DDAVP in childhood nocturnal enuresis.
Acta Paediatr Scand. 67:753-755, 1978
 158. Delaere KP, Strijbos WE: Antidiuretic approach with DDAVP for nocturnal enuresis.
Acta Urol Belg. 54:464-470, 1986
 159. Rushton HG: Nocturnal enuresis: epidemiology, evaluation, and currently available treatment options.
J Pediatr. 114:691-696, 1989
 160. Kruse S, Hellstrom AL, Hanson E, Hjalmas K, Sillen U: Treatment of primary monosymptomatic nocturnal enuresis with desmopressin: predictive factors.
BJU Int 88:572-576, 2001
 161. Matthiesen TB, Rittig S, Djurhuus JC, Norgaard JP: A dose titration, and an open 6-week efficacy and safety study of desmopressin tablets in the management of nocturnal enuresis.
J Urol 151:460-463, 1994

162. Miller K, Klauber GT: Desmopressin acetate in children with severe primary nocturnal enuresis.
Clin Ther 12:357-366, 1990
163. Rushton HG, Belman AB, Zaontz M, Skoog SJ, Sihelnik S: Response to desmopressin as a function of urine osmolality in the treatment of monosymptomatic nocturnal enuresis: a double-blind prospective study.
J Urol 154:749-753, 1995
164. Yap HK, Chao SM, Tan AY, Murugasu B, Ong EK, Low EH: Efficacy and safety of oral desmopressin in the treatment of primary nocturnal enuresis in Asian children.
J Paediatr Child Health 34:151-153, 1998
165. Skoog SJ, Stokes A, Turner KL: Oral desmopressin: a randomized double-blind placebo controlled study of effectiveness in children with primary nocturnal enuresis.
J Urol 158:1035-1040, 1997
166. Bamford MF, Cruickshank G: Dangers of intranasal desmopressin for nocturnal enuresis. J R Coll Gen Pract 39:345-346, 1989
167. Donoghue MB, Latimer ME, Pillsbury HL, Hertzog JH: Hyponatremic seizure in a child using desmopressin for nocturnal enuresis.
Arch Pediatr Adolesc Med 152:290-292, 1998
168. Kallio J, Rautava P, Huupponen R, Korvenranta H: Severe hyponatremia caused by intranasal desmopressin for nocturnal enuresis. Acta Paediatr 82:881-882, 1993
169. Odeh M, Oliven A: Coma and seizures due to severe hyponatremia and water intoxication in an adult with intranasal desmopressin therapy for nocturnal enuresis
J Clin Pharmacol 41:582-584, 2001
170. Robson WL, Norgaard JP, Leung AK: Hyponatremia in patients with nocturnal enuresis treated with DDAVP.
Eur J Pediatr. 155:959-962, 1996
171. Schwartz ID: Hyponatremic seizure in a child using desmopressin for nocturnal enuresis
Arch Pediatr Adolesc Med 152:1037-1038, 1998
172. Shindel A, Tobin G, Klutke C: Hyponatremia associated with desmopressin for the treatment of nocturnal polyuria.
Urology 60:344, 2002
173. Yaouyanc G, Jonville AP, Yaouyanc-Lapalle H, Barbier P, Dutertre JP, Autret E: Seizure with hyponatremia in a child prescribed desmopressin for nocturnal enuresis
J Toxicol Clin Toxicol 30:637-641, 1992
174. Eggert P, Kuhn B: Antidiuretic hormone regulation in patients with primary nocturnal enuresis.
Arch Dis Child 73:508-511, 1995

175. Aikawa T, Kasahara T, Uchiyama M: Circadian variation of plasma arginine vasopressin concentration, or arginine vasopressin in enuresis. *Scand J Urol Nephrol Suppl* 202:47-49, 1999
176. Lackgren G, Neveus T, Stenberg A: Diurnal plasma vasopressin and urinary output in adolescents with monosymptomatic nocturnal enuresis. *Acta Paediatr* 86:385-390, 1997
177. Steffens J, Netzer M, Isenberg E, Alloussi S, Ziegler M: Vasopressin deficiency in primary nocturnal enuresis. Results of a controlled prospective study. *Eur Urol* 24:366-370, 1993
178. Kawauchi A, Watanabe H, Miyoshi K: Early morning urine osmolality in nonenuretic and enuretic children. *Pediatr Nephrol* 10:696-698, 1996
179. Rascher W, Rauh W, Brandeis WE, Huber KH, Scharer K: Determinants of plasma arginine-vasopressin in children. *Acta Paediatr Scand.* 75:111-117, 1986
180. Radetti G, Paganini C, Rigon F, Gentili L, Gebert U, Ishikawa S: Urinary aquaporin-2 excretion in nocturnal enuresis. *Eur J Endocrinol.* 145:435-438, 2001
181. Valenti G, Laera A, Gouraud S, Pace G, Aceto G, Penza R, Selvaggi FP, Svelto M: Low-calcium diet in hypercalciuric enuretic children restores AQP2 excretion and improves clinical symptoms. *Am J Physiol Renal Physiol* 283:F895-F903, 2002
182. Aceto G, Penza R, Coccioli MS, Palumbo F, Cresta L, Cimador M, Chiozza ML, Caione P: Enuresis subtypes based on nocturnal hypercalciuria: a multicenter study. *J Urol* 170:1670-1673, 2003
183. Neveus T, Hansell P, Stenberg A: Vasopressin and hypercalciuria in enuresis: a reappraisal. *BJU Int* 90:725-729, 2002
184. Elian M, Elian E, Kaushansky A: Nocturnal enuresis: a familial condition. *J R Soc Med* 77:529-530, 1984
185. Abe K, Oda N, Hatta H: Behavioural genetics of early childhood: fears, restlessness, motion sickness and enuresis. *Acta Genet Med Gemellol (Roma)* 33:303-306, 1984
186. Hublin C, Kaprio J, Partinen M, Koskenvuo M: Nocturnal enuresis in a nationwide twin cohort. *Sleep* 21:579-585, 1998
187. Bakwin H: Enuresis in children. *J Pediatr* 58:806-819, 1961

188. Hallgren B: Nocturnal enuresis in twins. I. Methods and material. *Acta Psychiatr Scand* 35:73-90, 1960
189. Müller D, Suttorp M, Eggert P, Schlüter K, Simeoni E, Caliebe A, Schaub J: Diskordantes Auftreten von familiärer Enuresis nocturna bei monozygoten Zwillingen. [Abstract]. *Monatsschr Kinderheilkd* 144:113, 1996
190. Eiberg H, Berendt I, Mohr J: Assignment of dominant inherited nocturnal enuresis (ENUR1) to chromosome 13q. *Nat Genet* 10:354-356, 1995
191. Arnell H, Hjalmas K, Jagervall M, Lackgren G, Stenberg A, Bengtsson B, Wassen C, Emahazion T, Anneren G, Pettersson U, Sundvall M, Dahl N: The genetics of primary nocturnal enuresis: inheritance and suggestion of a second major gene on chromosome 12q. *J Med Genet* 34:360-365, 1997
192. Eiberg H: Total genome scan analysis in a single extended family for primary nocturnal enuresis: evidence for a new locus (ENUR3) for primary nocturnal enuresis on chromosome 22q11. *Eur Urol* 33 Suppl 3:34-36, 1998
193. Von Gontard A, Eiberg H, Hollmann E, Rittig S, Lehmkuhl G: Molecular genetics of nocturnal enuresis: linkage to a locus on chromosome 22. *Scand J Urol Nephrol Suppl* 202:76-80, 1999
194. Deen PM, Dahl N, Caplan MJ: The aquaporin-2 water channel in autosomal dominant primary nocturnal enuresis. *J Urol* 167:1447-1450, 2002
195. Arnell H: The genetics of nocturnal enuresis: a simple question of complexity. *Acta Paediatr* 87:487-488, 1998
196. Von Gontard A, Schaumburg H, Hollmann E, Eiberg H, Rittig S: The genetics of enuresis: a review. *J Urol* 166:2438-2443, 2001
197. Gonzalez-Perrett S, Kim K, Ibarra C, Damiano AE, Zotta E, Batelli M, Harris PC, Reisin IL, Arnaout MA, Cantiello HF: Polycystin-2, the protein mutated in autosomal dominant polycystic kidney disease (ADPKD), is a Ca²⁺-permeable nonselective cation channel. *Proc Natl Acad Sci U S A* 98:1182-1187, 2001
198. Hoenderop JG, Hartog A, Stuiver M, Doucet A, Willems PH, Bindels RJ: Localization of the epithelial Ca(2+) channel in rabbit kidney and intestine. *J Am Soc Nephrol* 11:1171-1178, 2000
199. Van Cromphaut SJ, Dewerchin M, Hoenderop JG, Stockmans I, Van Herck E, Kato S, Bindels RJ, Collen D, Carmeliet P, Bouillon R, Carmeliet G: Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspects. *Proc Natl Acad Sci U S A* 98:13324-13329, 2001

200. Lambers TT, Weidema AF, Nilius B, Hoenderop JG, Bindels RJ: Regulation of the Mouse Epithelial Ca²⁺ Channel TRPV6 by the Ca²⁺-sensor Calmodulin
J Biol Chem 279:28855-28861, 2004
201. Gkika D, Mahieu F, Nilius B, Hoenderop JG, Bindels RJ: 80K-H as a new Ca²⁺ sensor regulating the activity of the epithelial Ca²⁺ channel transient receptor potential cation channel V5 (TRPV5).
J Biol Chem 279:26351-26357, 2004
202. van de Graaf SF, Hoenderop JG, Gkika D, Lamers D, Prenen J, Rescher U, Gerke V, Staub O, Nilius B, Bindels RJ: Functional expression of the epithelial Ca(2+) channels (TRPV5 and TRPV6) requires association of the S100A10-annexin 2 complex.
EMBO J 22:1478-1487, 2003
203. Hoenderop JG, Voets T, Hoefs S, Weidema F, Prenen J, Nilius B, Bindels RJ: Homo- and heterotetrameric architecture of the epithelial Ca²⁺ channels TRPV5 and TRPV6.
EMBO J 22:776-785, 2003
204. Hoenderop JG, van Leeuwen JP, van der Eerden BC, Kersten FF, van der Kemp AW, Merillat AM, Waarsing JH, Rossier BC, Vallon V, Hummler E, Bindels RJ: Renal Ca²⁺ wasting, hyperabsorption, and reduced bone thickness in mice lacking TRPV5.
J Clin Invest 112:1906-1914, 2003
205. Nilius B, Prenen J, Vennekens R, Hoenderop JG, Bindels RJ, Droogmans G: Modulation of the epithelial calcium channel, ECaC, by intracellular Ca²⁺.
Cell Calcium 29:417-428, 2001
206. Vennekens R, Prenen J, Hoenderop JG, Bindels RJ, Droogmans G, Nilius B: Modulation of the epithelial Ca²⁺ channel ECaC by extracellular pH.
Pflugers Arch. 442:237-242, 2001
207. Nilius B, Weidema F, Prenen J, Hoenderop JG, Vennekens R, Hoefs S, Droogmans G, Bindels RJ: The carboxyl terminus of the epithelial Ca(2+) channel ECaC1 is involved in Ca(2+)-dependent inactivation.
Pflugers Arch. 445:584-588, 2003
208. Nilius B, Vennekens R, Prenen J, Hoenderop JG, Droogmans G, Bindels RJ: The single pore residue Asp542 determines Ca²⁺ permeation and Mg²⁺ block of the epithelial Ca²⁺ channel. *J Biol Chem* 276:1020-1025, 2001
209. Nilius B, Vennekens R, Prenen J, Hoenderop JG, Bindels RJ, Droogmans G: Whole-cell and single channel monovalent cation currents through the novel rabbit epithelial Ca²⁺ channel ECaC. *J Physiol* 527:239-248, 2000
210. Nijenhuis T, Hoenderop JG, van der Kemp AW, Bindels RJ: Localization and regulation of the epithelial Ca²⁺ channel TRPV6 in the kidney.
J Am Soc Nephrol 14:2731-2740, 2003
211. Morita Kazumasa, Furuse Mikio, Fujimoto Kazushi, Tsukita Shoichiro: Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. *Proc Natl Acad Sci U S A* 96:511-516, 2004

212. Kiuchi-Saishin Y, Gotoh S, Furuse M, Takasuga A, Tano Y, Tsukita S: Differential expression patterns of claudins, tight junction membrane proteins, in mouse nephron segments. *J Am Soc Nephrol* 13:875-886, 2002
213. Li WY, Huey CL, Yu AS: Expression of claudin-7 and -8 along the mouse nephron *Am J Physiol Renal Physiol* 286:F1063-F1071, 2004
214. Reyes JL, Lamas M, Martin D, del Carmen NM, Islas S, Luna J, Tauc M, Gonzalez-Mariscal L: The renal segmental distribution of claudins changes with development. *Kidney Int* 62:476-487, 2002
215. Weber S, Schneider L, Peters M, Misselwitz J, Ronnefarth G, Boswald M, Bonzel KE, Seeman T, Sulakova T, Kuwertz-Broking E, Gregoric A, Palcoux JB, Tasic V, Manz F, Scharer K, Seyberth HW, Konrad M: Novel paracellin-1 mutations in 25 families with familial hypomagnesemia with hypercalciuria and nephrocalcinosis. *J Am Soc Nephrol* 12:1872-1881, 2001
216. Wolf MT, Dotsch J, Konrad M, Boswald M, Rascher W: Follow-up of five patients with FHHNC due to mutations in the Paracellin-1 gene. *Pediatr Nephrol* 17:602-608, 2002
217. Amasheh S, Meiri N, Gitter AH, Schoneberg T, Mankertz J, Schulzke JD, Fromm M: Claudin-2 expression induces cation-selective channels in tight junctions of epithelial cells. *J Cell Sci* 115:4969-4976, 2002
218. Colegio OR, Van Itallie CM, McCrea HJ, Rahner C, Anderson JM: Claudins create charge-selective channels in the paracellular pathway between epithelial cells. *Am J Physiol Cell Physiol* 283:C142-C147, 2002
219. Jeansonne B, Lu Q, Goodenough DA, Chen YH: Claudin-8 interacts with multi-PDZ domain protein 1 (MUPP1) and reduces paracellular conductance in epithelial cells. *Cell Mol Biol (Noisy-le-grand)* 49:13-21, 2003
220. Yu AS, Enck AH, Lencer WI, Schneeberger EE: Claudin-8 expression in Madin-Darby canine kidney cells augments the paracellular barrier to cation permeation *J Biol Chem* 278:17350-17359, 2003
221. Van Itallie C, Rahner C, Anderson JM: Regulated expression of claudin-4 decreases paracellular conductance through a selective decrease in sodium permeability. *J Clin Invest* 107:1319-1327, 2001
222. Glynn PA, Evans TJ: Role of the PDZ scaffolding protein in tubule cells in maintenance of polarised function. *Exp Nephrol* 10:307-312, 2002
223. Swiatecka-Urban A, Duhaim M, Coutermarsh B, Karlson KH, Collawn J, Milewski M, Cutting GR, Guggino WB, Langford G, Stanton BA: PDZ domain interaction controls the endocytic recycling of the cystic fibrosis transmembrane conductance regulator. *J Biol Chem* 277:40099-40105, 2002

224. Tomita S, Nicoll RA, Brecht DS: PDZ Protein Interactions Regulating Glutamate Receptor Function and Plasticity. *J Cell Biol* 153:19F-24, 2001
225. Short DB, Trotter KW, Reczek D, Kreda SM, Bretscher A, Boucher RC, Stutts MJ, Milgram SL: An apical PDZ protein anchors the cystic fibrosis transmembrane conductance regulator to the cytoskeleton. *J Biol Chem* 273:19797-19801, 1998
226. Moyer BD, Denton J, Karlson KH, Reynolds D, Wang S, Mickle JE, Milewski M, Cutting GR, Guggino WB, Li M, Stanton BA: A PDZ-interacting domain in CFTR is an apical membrane polarization signal. *J Clin Invest* 104:1353-1361, 1999
227. Itoh M, Furuse M, Morita K, Kubota K, Saitou M, Tsukita S: Direct Binding of Three Tight Junction-associated MAGUKs, ZO-1, ZO-2, and ZO-3, with the COOH Termini of Claudins. *J Cell Biol* 147:1351-1363, 1999
228. Weber S, Schneider L, Peters M, Misselwitz J, Ronnefarth G, Boswald M, Bonzel KE, Seeman T, Sulakova T, Kuwertz-Broking E, Gregoric A, Palcoux JB, Tasic V, Manz F, Scharer K, Seyberth HW, Konrad M: Novel paracellin-1 mutations in 25 families with familial hypomagnesemia with hypercalciuria and nephrocalcinosis. *J Am Soc Nephrol* 12:1872-1881, 2001
229. Wolf MT, Dotsch J, Konrad M, Boswald M, Rascher W: Follow-up of five patients with FHHNC due to mutations in the Paracellin-1 gene. *Pediatr Nephrol* 17:602-608, 2002
230. Norgaard JP, Rittig S, Djurhuus JC: Nocturnal enuresis: an approach to treatment based on pathogenesis. *J Pediatr* 114:705-710, 1989
231. Brock JW, III: The frequency and frequency dysuria syndromes of childhood: hypercalciuria as a possible etiology. *Urology* 44:411-412, 1994
232. van Baal J, Raber G, de Slegte J, Pieters R, Bindels RJ, Willems PH: Vasopressin-stimulated Ca²⁺ reabsorption in rabbit cortical collecting system: effects on cAMP and cytosolic Ca²⁺. *Pflugers Arch* 433:109-115, 1996
233. Eggert P, Chavez-Kattau K, Muller D: Age- and weight-related dosage of dDAVP in the treatment of primary nocturnal enuresis. *Klin Padiatr* 213:317-320, 2001
234. Hjalmas K, Hanson E, Hellstrom AL, Kruse S, Sillen U: Long-term treatment with desmopressin in children with primary monosymptomatic nocturnal enuresis: an open multicentre study. Swedish Enuresis Trial (SWEET) Group. *Br J Urol* 82:704-709, 1998
235. Uygur MC, Ozgu IH, Ozen H, Ozen S, Toklu C, Ergen A, Tekgul S, Remzi D: Long-term treatment of nocturnal enuresis with desmopressin intranasal spray. *Clin Pediatr (Phila)* 36:455-459, 1997
236. Chiozza ML, Del Gado R, Di Toro R, Ferrara P, Fois A, Giorgi P, Giovannini M, Rottoli A, Segni G, Biraghi M: Italian multicentre open trial on DDAVP spray in nocturnal enuresis. *Scand J Urol Nephrol* 33:42-48, 1999

237. Lackgren G, Lilja B, Neveus T, Stenberg A: Desmopressin in the treatment of severe nocturnal enuresis in adolescents--a 7-year follow-up study. *Br J Urol* 81 Suppl 3:17-23, 1998
238. Stenberg A, Lackgren G: Desmopressin tablet treatment in nocturnal enuresis. *Scand J Urol Nephrol Suppl* 173:95-99, 1995
239. Vulliamy D: The day and night output of urine in enuresis. *Arch Dis Child* 31:439-443, 1959
240. Ramsden PD, Hindmarsh JR, Price DA, Yeates WK, Bowditch JD: DDAVP for adult enuresis--a preliminary report. *Br J Urol* 54:256-258, 1982
241. Devitt H, Holland P, Butler R, Redfern E, Hiley E, Roberts G: Plasma vasopressin and response to treatment in primary nocturnal enuresis. *Arch Dis Child* 80:448-451, 1999
242. Liedtke W, Tobin DM, Bargmann CI, Friedman JM: Mammalian TRPV4 (VR-OAC) directs behavioral responses to osmotic and mechanical stimuli in *Caenorhabditis elegans*. *Proc Natl Acad Sci U S A* 100 Suppl 2:14531-14536, 2003
243. Liedtke W, Friedman JM: Abnormal osmotic regulation in *trpv4*^{-/-} mice. *Proc Natl Acad Sci U S A* 100:13698-13703, 2003
244. Mizuno A, Matsumoto N, Imai M, Suzuki M: Impaired osmotic sensation in mice lacking TRPV4. *Am J Physiol Cell Physiol* 285:C96-101, 2003
245. Weingartner H, Gold P, Ballenger JC, Smallberg SA, Summers R, Rubinow DR, Post RM, Goodwin FK: Effects of vasopressin on human memory functions. *Science* 211:601-603, 1981
246. Gold PW, Weingartner H, Ballenger JC, Goodwin FK, Post RM: Effects of 1-desamino-8-D-arginine vasopressin on behaviour and cognition in primary affective disorder. *Lancet* 2:992-994, 1979
247. Audibert A, Moeglen JM, Lancranjan I: Central effects of vasopressin in man. *Int J Neurol* 14:162-174, 1980
248. Burbach JP, Kovacs GL, De Wied D, Van Nispen JW, Greven HM: A major metabolite of arginine vasopressin in the brain is a highly potent neuropeptide. *Science* 221:1310-1312, 1983
249. De Wied D, Gaffori O, van Ree JM, de Jong W: Central target for the behavioural effects of vasopressin neuropeptides. *Nature* 308:276-278, 1984
250. De Wied D, Diamant M, Fodor M: Central nervous system effects of the neurohypophyseal hormones and related peptides. *Front Neuroendocrinol* 14:251-302, 1993

251. Fehm-Wolfsdorf G, Born J, Voigt KH, Fehm HL: Behavioral effects of vasopressin
Neuropsychobiology 11:49-53, 1984
252. Ritvo ER, Ornitz EM, Gottlieb F, Poussaint AF, Maron BJ, Ditman KS, Blinn KA:
Arousal and nonarousal enuretic events.
Am J Psychiatry 126:77-84, 1969
253. Bader G, Neveus T, Kruse S, Sillen U: Sleep of primary enuretic children and
controls. *Sleep* 25:579-583, 2002
254. Norgaard JP, Hansen JH, Nielsen JB, Rittig S, Djurhuus JC: Nocturnal studies in
enuretics. A polygraphic study of sleep-EEG and bladder activity. *Scand.J Urol
Nephrol Suppl* 125:73-78, 1989
255. Ornitz EM, Russell AT, Hanna GL, Gabikian P, Gehricke J-G, Song D, Guthrie D:
Prepulse inhibition of startle and the neurobiology of primary nocturnal enuresis. *Biol
Psychiatry* 45:1455-1466, 1999
256. Griffiths DJ: The pontine micturition centres. *Scand J Urol Nephrol Suppl*21-26, 2002
257. Barrington FJ: The effect of lesions in the hind- and midbrain on micturition in the cat.
Quart J Exp Physiol Cogn Med 15:81-102, 1925
258. Blok BF, Holstege G: The central control of micturition and continence: implications
for urology. *BJU Int* 83 Suppl 2:1-6, 1999
259. Blok BF, Willemsen AT, Holstege G: A PET study on brain control of micturition in
humans.
Brain 120:111-121, 1997
260. Blok BF, Holstege G: Direct projections from the periaqueductal gray to the pontine
micturition center (M-region). An anterograde and retrograde tracing study in the cat.
Neurosci Lett 166:93-96, 1994
261. Page ME, Akaoka H, Aston-Jones G, Valentino RJ: Bladder distention activates
noradrenergic locus coeruleus neurons by an excitatory amino acid mechanism.
Neuroscience 51:555-563, 1992
262. Vanderhorst VG, Mouton LJ, Blok BF, Holstege G: Distinct cell groups in the
lumbosacral cord of the cat project to different areas in the periaqueductal gray. *J
Comp Neurol* 376:361-385, 1996
263. Blok BF, Willemsen AT, Holstege G: A PET study on brain control of micturition in
humans. *Brain* 120:111-121, 1997
264. Gjone R: Excitatory and inhibitory bladder responses to stimulation of 'limbic',
diencephalic and mesencephalic structures in the cat
Acta Physiol Scand. 66:91-102, 1966
265. Kato Y, Igarashi N, Hirasawa A, Tsujimoto G, Kobayashi M: Distribution and
developmental changes in vasopressin V2 receptor mRNA in rat brain.
Differentiation 59:163-169, 1995

266. Hirasawa A, Hashimoto K, Tsujimoto G: Distribution and developmental change of vasopressin V1A and V2 receptor mRNA in rats.
Eur J Pharmacol. 267:71-75, 1994
267. Watanabe H, Kawauchi A: Locus coeruleus function in enuresis.
Scand J Urol Nephrol Suppl 202:14-17, 1999
268. Nitz D, Siegel JM: GABA release in the locus coeruleus as a function of sleep/wake state.
Neuroscience 78:795-801, 1997
269. Janaky T, Laszlo FA, Sirokman F, Morgat JL: Biological half-life and organ distribution of [3H]8-arginine-vasopressin in the rat.
J Endocrinol 93:295-303, 1982
270. Müller D, Eggert P: Intranasal verabreichtes Desmopressin erhöht die mRNA Expression von Prä-Pro-Orexin: Bedeutung für die Behandlung der Enuresis Nocturna [Abstract]. Monatsschr Kinderheilkd 151: 2003
271. Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL: Sniffing neuropeptides: a transnasal approach to the human brain.
Nat Neurosci 5:514-516, 2002
272. Rahmani HR, Ingram CD: Characterisation of vasopressin V1a binding sites in the ovine olfactory bulb.
Neurosci Lett 220:33-36, 1996
273. Pietrowsky R, Struben C, Molle M, Fehm HL, Born J: Brain potential changes after intranasal vs. intravenous administration of vasopressin: evidence for a direct nose-brain pathway for peptide effects in humans.
Biol.Psychiatry 39:332-340, 1996
274. Ebenezer IS: The effects of subcutaneous administration of arginine-8-vasopressin on the electroencephalogram of conscious rats are mediated by peripheral vasopressin V1 receptors.
Methods Find Exp Clin.Pharmacol 16:315-321, 1994
275. Choonara IA: Sodium valproate and enuresis.
Lancet 1:1276, 1985
276. Panayiotopoulos CP: Nocturnal enuresis associated with sodium valproate.
Lancet 1:980-981, 1985
277. Eggert P, Muhle H, Stephani U, Ernst JP, Müller D: On the occurrence of monosymptomatic nocturnal enuresis in children treated with valproate, and its therapy with dDAVP [Abstract]. ICS Proceedings, 2003
278. Kreuz W, Linde R, Funk M, Meyer-Schrod R, Foll E, Nowak-Gottl U, Jacobi G, Vigh Z, Scharer I: Induction of von Willebrand disease type I by valproic acid.
Lancet 335:1350-1351, 1990

279. Kreuz W, Linde R, Funk M, Meyer-Schrod R, Foll E, Nowak-Gottl U, Jacobi G, Vigh Z, Scharrer I: Valproate therapy induces von Willebrand disease type I. *Epilepsia* 33:178-184, 1992
280. Serdaroglu G, Tutuncuoglu S, Kavakli K, Tekgul H: Coagulation abnormalities and acquired von Willebrand's disease type 1 in children receiving valproic acid. *J Child Neurol* 17:41-43, 2002
281. Teich M, Longin E, Dempfle CE, Konig S: Factor XIII deficiency associated with valproate treatment. *Epilepsia* 45:187-189, 2004
282. Danguir J: Sleep deficits in rats with hereditary diabetes insipidus. *Nature* 304:163-164, 1983
283. de Weid D, Bohus B, Wimersma Greidanus TB: Memory deficit in rats with hereditary diabetes insipidus. *Brain Res* 85:152-156, 1975
284. Born J, Kellner C, Uthgenannt D, Kern W, Fehm HL: Vasopressin regulates human sleep by reducing rapid-eye-movement sleep. *Am J Physiol* 262:E295-E300, 1992
285. Doris PA: Vasopressin and central integrative processes. *Neuroendocrinology* 38:75-85, 1984
286. Fehm-Wolfsdorf G, Born J, Voigt KH, Fehm HL: Human memory and neurohypophyseal hormones: opposite effects of vasopressin and oxytocin. *Psychoneuroendocrinology* 9:285-292, 1984
287. Jobert M, Jahnig P, Schulz H: Effect of two antidepressant drugs on REM sleep and EMG activity during sleep. *Neuropsychobiology* 39:101-109, 1999
288. McCulloch K, Brouillette RT, Guzzetta AJ, Hunt CE: Arousal responses in near-miss sudden infant death syndrome and in normal infants. *J Pediatr* 101:911-917, 1982
289. Kahn A, Groswasser J, Franco P, Scaillet S, Sawaguchi T, Kelmanson I, Dan B: Sudden infant deaths: stress, arousal and SIDS. *Pathophysiology* 10:241-252, 2004
290. Sawaguchi T, Franco P, Groswasser J, Kahn A: Partial arousal deficiency in SIDS victims and noradrenergic neuronal plasticity. *Early Hum Dev* 75 Suppl:S61-S64, 2003
291. Sawaguchi T, Franco P, Groswasser J, Kahn A: Partial arousal deficiency in SIDS victims and noradrenergic neuronal plasticity. *Pathophysiology* 10:185-187, 2004
292. Sawaguchi T, Franco P, Kato I, Shimizu S, Kadhim H, Groswasser J, Sottiaux M, Togari H, Kobayashi M, Takashima S, Nishida H, Sawaguchi A, Kahn A: From physiology to pathology: arousal deficiency theory in sudden infant death syndrome (SIDS)--with reference to apoptosis and neuronal plasticity. *Forensic Sci Int* 130 Suppl:37-43, 2002

293. Chan J, Edman JC, Koltai PJ: Obstructive sleep apnea in children. *Am Fam Physician* 69:1147-1154, 2004
294. Groswasser J, Simon T, Scaillet S, Franco P, Kahn A: Reduced arousals following obstructive apneas in infants sleeping prone. *Pediatr Res* 49:402-406, 2001
295. Brooks LJ, Topol HI: Enuresis in children with sleep apnea. *J Pediatr*. 142:515-518, 2003
296. Robson WL, Jackson HP, Blackhurst D, Leung AK: Enuresis in children with attention-deficit hyperactivity disorder. *South Med J* 90:503-505, 1997
297. Fergusson DM, Horwood LJ: Nocturnal enuresis and behavioral problems in adolescence: a 15-year longitudinal study. *Pediatrics* 94:662-668, 1994
298. Bailey JN, Ornitz EM, Gehricke JG, Gabikian P, Russell AT, Smalley SL: Transmission of primary nocturnal enuresis and attention deficit hyperactivity disorder. *Acta Paediatr* 88:1364-1368, 1999
299. Ornitz EM, Hanna GL, De Traversay J: Prestimulation-induced startle modulation in attention-deficit hyperactivity disorder and nocturnal enuresis. *Psychophysiology* 29:437-451, 1992
300. Duel BP, Steinberg-Epstein R, Hill M, Lerner M: A survey of voiding dysfunction in children with attention deficit-hyperactivity disorder. *J Urol* 170:1521-1523, 2003

